1-phenyl-2-palmitoylamino-3-morpholino-1-propanol has been researched along with Acute Lymphoid Leukemia in 1 studies
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol: a sphingolipid analog; inhibits the enzyme activity in infected erythrocytes
N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]hexadecanamide : A fatty amide resulting from the formal condensation of palmitic acid with the primary amino group of 2-amino-3-(morpholin-4-yl)-1-phenylpropan-1-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Donnell, PH | 1 |
| Guo, WX | 1 |
| Reynolds, CP | 1 |
| Maurer, BJ | 1 |
1 other study available for 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
Topics: Antineoplastic Agents; Cell Survival; Ceramides; Dose-Response Relationship, Drug; Drug Synergism; F | 2002 |